Jody A. Charnow

Investigators performed a subgroup analysis of the phase 3 ARASENS trial.

Grade 2 or higher gastrointestinal toxicities after hypofractionated prostate cancer radiation therapy occurred in a significantly lower proportion of men who received a hyaluronic acid spacer compared with those who did not.

Investigators estimated prevalence based on the number of de novo and recurrent cases of metastatic prostate cancer.

Phosphodiesterase-5 inhibitor use after robotic prostate cancer surgery was associated with a 57% lower risk of death.

A 4Kscore of 20% or higher is independently associated with a 1.7-fold increased risk for disease progression compared with a lower score, a study revealed.